Novel PET imaging agent targets copper in tumors, detects prostate cancer recurrence early

March 6, 2018, Society of Nuclear Medicine and Molecular Imaging
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Credit: A Piccardo et al., Galliera Hospital, Genoa, Italy

An Italian study featured in the March issue of the Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse as indicated by rising prostate-specific antigen (PSA) levels.

Copper tends to be more concentrated in tumors, making it a good imaging biomarker. For this study of 50 patients, researchers conducted PET/CT scans comparing the new imaging agent, copper-64 chloride (64CuCl2), with fluorine-18-choline (18F-Choline). Multiparametric (mpMRI) was also conducted. In addition to calculating the detection rate of each imaging modality, the biodistribution, kinetics of the lesions and radiation dosimetry of 64CuCl2 were evaluated.

"This is the first time this novel agent has been compared with 18F-Choline-PET/CT in a considerable number of prostate cancer patients with biochemical relapse," explains Arnoldo Piccardo, of E.O. Ospedali Galliera in Genoa, Italy. He points out, "Early detection of prostate cancer relapse may improve the clinical management of patients, for example implementing early salvage radiotherapy."

The effective dose of 64CuCl2 was determined to be 5.7 mSv, similar to those of other established PET tracers (although higher than for 18F-Choline, which is 4 mSv). Unlike 18F-Choline, 64CuCl2 is neither accumulated in, nor excreted from, the urinary tract (main uptake is in the liver); this allows for thorough pelvic assessment, increasing the possibility of identifying small lesions close to the bladder. No adverse reactions were observed after the injection of 64CuCl2, and results show that 64CuCl2-PET/CT has a higher detection rate than 18F-Choline-PET/CT in patients with low levels of PSA (<1 ng/ml).

"This study determined that the biodistribution of 64CuCl2 is more suitable than that of 18F-Choline for exploring the pelvis and prostatic bed," says Piccardo. "In with biochemical relapse and a low PSA level, 64CuCl2-PET/CT shows a significantly higher detection rate than 18F-Choline-PET/CT." He reports, "Larger trials with this PET tracer are expected to further define its capabilities and role in the management of ."

Explore further: Researchers map prostate cancer relapse using C-11 choline PET and MRI

More information: Arnoldo Piccardo et al, 64CuCl2PET/CT in Prostate Cancer Relapse, Journal of Nuclear Medicine (2017). DOI: 10.2967/jnumed.117.195628

Related Stories

Researchers map prostate cancer relapse using C-11 choline PET and MRI

October 5, 2016
A team of Mayo Clinic researchers has, for the first time, successfully mapped patterns of prostate cancer recurrence, following surgery. Using C-11 choline PET imaging and multiparametric MRI, researchers found an anatomically ...

PSMA PET/CT visualizes prostate cancer recurrence early, impacts radiation therapy

February 1, 2018
A nuclear medicine scan may locate prostate cancer recurrence after radical prostatectomy early after disease recurrence and could help guide salvage radiotherapy, according to new research from the University of California ...

Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer

November 8, 2012
Mayo Clinic has received U.S. Food and Drug Administration approval to produce and administer Choline C 11 Injection, an imaging agent used during a positron emission tomography (PET) scan to help detect sites of recurrent ...

Trio of studies support use of PET/CT scans as prostate cancer staging tool

October 21, 2011
Recent studies have suggested that C-11 choline positron emission tomography/computerized tomography (PET/CT) scans can be utilized as a staging and potentially therapeutic tool in prostate cancer. The results of three studies, ...

First human application of novel PET tracer for prostate cancer

August 7, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), ...

PET/MR effective for imaging recurrent prostate cancer

June 11, 2013
When prostate cancer makes a comeback, it becomes increasingly important to have exceptional imaging available to find all possible regions where cancer has spread to other parts of the body, or metastasized, in order to ...

Recommended for you

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

Genomics offers new treatment options for infants with range of soft tissue tumors

June 18, 2018
The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed ...

Standard myelofibrosis drug can awaken 'dormant' lymphoma

June 18, 2018
Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life ...

Breast cancer researcher warns against online genetic tests

June 18, 2018
We have never been so fascinated by the secrets inside our cells.

Non-coding DNA reveals a route by which advanced prostate cancer resists treatment

June 15, 2018
Two research teams converge on epigenetic switches that feed treatment-resistant metastatic prostate tumors. This research highlights the value of exploring gene regulation and large-scale structural changes in the cancer ...

Researchers peer inside cells to spy on cancer's on-off switch

June 15, 2018
Forty years after researchers first discovered it in fruit flies, a once-obscure cluster of proteins called PRC2 has become a key target for new cancer-fighting drugs, due to its tendency—when mutated—to bind to and silence ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.